Report cover image

Diabetic Cardiomyopathy - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 40 Pages
SKU # DEL18679462

Description

Diabetic Cardiomyopathy - Pipeline Insight, 2024



DelveInsight’s, “Diabetic Cardiomyopathy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Diabetic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Diabetic Cardiomyopathy Understanding

Diabetic Cardiomyopathy: Overview

Diabetic cardiomyopathy is a type of cardiovascular damage present in patients suffering from diabetes. It is characterized by myocardial dilatation and hypertrophy as well as a decrease in the systolic and diastolic functions of the left ventricle, and its presence is independent of the coexistence of ischemic heart disease or hypertension. Existence of this condition in a diabetic patient may have several therapeutic implications including: improving glycemic control, earlier use of calcium channel blockers (CCBs), ACE inhibitors and ARBs, exercise training, lipid-lowering therapy, and antioxidant and insulin-sensitizing drugs. Increasing evidence suggests that hyperglycemia is central to the pathogenesis of diabetic cardiomyopathy, which triggers a series of maladaptive events leading to cardiomyocyte apoptosis, collagen deposition, and cardiac fibrosis.

""Diabetic Cardiomyopathy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Diabetic Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Cardiomyopathy.
Diabetic Cardiomyopathy Emerging Drugs Chapters

This segment of the Diabetic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Cardiomyopathy Emerging Drugs
  • IMB-1018972: Imbria Pharmaceuticals
Mechanism of Action: Partial fatty acid oxidation inhibitors. Currently under phase 2 of clinical trials for the treatment of diabetic cardiaomyopathy
  • AT-001: Applied Therapeutics
AT-001 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed as an oral therapy for the treatment of Diabetic Cardiomyopathy (DbCM). Applied Therapeutics initiated a Phase 3 registrational study in DbCM with this potent and selective agent in September 2019.

Further product details are provided in the report……..

Diabetic Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Diabetic Cardiomyopathy
There are approx. 3+ key companies which are developing the therapies for Diabetic Cardiomyopathy. The companies which have their Diabetic Cardiomyopathy drug candidates in the mid to advanced stage, i.e. phase II include, Imbria Pharmaceuticals and others.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like
  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
Route of Administration

Diabetic Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Cardiomyopathy drugs.

Diabetic Cardiomyopathy Report Insights
  • Diabetic Cardiomyopathy Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Diabetic Cardiomyopathy Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Diabetic Cardiomyopathy drugs?
  • How many Diabetic Cardiomyopathy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Cardiomyopathy?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Cardiomyopathy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Diabetic Cardiomyopathy and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Imbria Pharmaceuticals
  • Applied Therapeutics
Key Products
  • IMB-1018972
  • AT-001

Table of Contents

40 Pages
Introduction
Executive Summary
Diabetic Cardiomyopathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Diabetic Cardiomyopathy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Diabetic Cardiomyopathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Diabetic Cardiomyopathy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
AT-001: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-101897: Imbria Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Diabetic Cardiomyopathy Key Companies
Diabetic Cardiomyopathy Key Products
Diabetic Cardiomyopathy- Unmet Needs
Diabetic Cardiomyopathy- Market Drivers and Barriers
Diabetic Cardiomyopathy- Future Perspectives and Conclusion
Diabetic Cardiomyopathy Analyst Views
Diabetic Cardiomyopathy Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us